![](/images/graphics-bg.png)
Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
Joint Authors
Skljarevski, Vladimir
Dueñas Tentori, Héctor J.
Frakes, Elijah P.
Heinloth, Alexandra N.
Sagman, Doron
Lipsius, Sarah
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-08-29
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
We summarize efficacy and safety findings from 4 double-blind, placebo-controlled, 12-week studies and 1 open-label, uncontrolled, 34-week maintenance-of-effect (MOE) study that examine duloxetine 40 and 60 mg once daily (QD) in patients with diabetic peripheral neuropathic pain (DPNP).
In all placebo-controlled studies, duloxetine showed significantly (P≤.01) greater reduction in pain severity (weekly mean of 24-hour average pain severity ratings, primary outcome measure) compared with placebo.
In all placebo-controlled studies, duloxetine showed significantly (P≤.05) greater improvement on brief pain inventory-Interference ratings.
Patient global impression of improvement ratings were superior to placebo (P≤.01) for duloxetine patients in all placebo-controlled studies.
Response rates (based on 30% pain reduction) ranged from 57% to 68% for duloxetine and from 35% to 47% for placebo and were statistically significantly different (P≤.01) between treatment groups in 3 out of 4 studies.
The open-label study showed maintenance of analgesic effect of duloxetine in DPNP.
In the duloxetine groups, 4.3% to 14.9% of patients discontinued because of adverse events (placebo groups: 2.6% to 7.4%).
Most commonly reported treatment-emergent adverse events were nausea, somnolence, and headache.
Duloxetine 40 and 60 mg QD was efficacious and well tolerated in the management of DPNP.
American Psychological Association (APA)
Skljarevski, Vladimir& Frakes, Elijah P.& Sagman, Doron& Lipsius, Sarah& Heinloth, Alexandra N.& Dueñas Tentori, Héctor J.. 2012. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment،Vol. 2012, no. 2012, pp.1-12.
https://search.emarefa.net/detail/BIM-506465
Modern Language Association (MLA)
Skljarevski, Vladimir…[et al.]. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment No. 2012 (2012), pp.1-12.
https://search.emarefa.net/detail/BIM-506465
American Medical Association (AMA)
Skljarevski, Vladimir& Frakes, Elijah P.& Sagman, Doron& Lipsius, Sarah& Heinloth, Alexandra N.& Dueñas Tentori, Héctor J.. Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain. Pain Research and Treatment. 2012. Vol. 2012, no. 2012, pp.1-12.
https://search.emarefa.net/detail/BIM-506465
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-506465